Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy

Affiliations

¹ The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: lulla@bcm.edu.
² The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

Comment

Premal Lulla et al. Mol Ther. 2017.

. 2017 Jan 4;25(1):8-9.

doi: 10.1016/j.ymthe.2016.12.002. Epub 2017 Jan 4.

¹ The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: lulla@bcm.edu.
² The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

No abstract available

Figures

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Locke FL, et al. Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4. Mol Ther. 2017. PMID: 28129122 Free PMC article. Clinical Trial.

1. Kochenderfer J.N., Dudley M.E., Kassim S.H., Somerville R.P.T., Carpenter R.O., Stetler-Stevenson M., Yang J.C., Phan G.Q., Hughes M.S., Sherry R.M. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 2015;33:540–549. - PMC - PubMed
1. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014;371:1507–1517. - PMC - PubMed
1. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., Bartido S., Stefanski J., Taylor C., Olszewska M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013;5:177ra38. - PMC - PubMed
1. Locke F.L., Neelapu S.S., Bartlett N., Siddiqi T., Chavez J.C., Hosing C.M., Ghobadi A., Budde L.E., Bot A., Rossi J.M. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2016;25:285–295. this issue. - PMC - PubMed
1. Crump M., Neelapu S.S., Farooq U., Neste E.V.D., Kuruvilla J., Ahmed M.A. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J. Clin. Oncol. 2016;34 abstr 7516.